Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Biophytis ontploft, Integragen en Theradiag next!
Volgen
Het Franse aandeel Biophytis ging deze week maar liefst 30% hoger. Waarom dan? Nou, ze hebben recent geld opgehaald en Braknor Fund heeft een belang. Het gaat deze jongens natuurlijk maar om 1 ding en dat is geld verstrekken en vervolgens er meer geld uit halen. Maar het is super goed voor het sentiment. De kans is dan ook groot dat achtergebleven en recent gefinancierde bedrijven ook een koerssprong kunnen maken. Ik heb 2 kandidaten: Theradiag en Integragen. Om met de laatste te beginnen: aantal uitstaande aandelen: 6 536 944 42% in vaste handen huidige marktwaarde: 19 miljoen 3.7 mln opgehaald in februari tegen EUR 2.53 Uit een recente presentatie worden de volgende doelen voor de komende 12 maanden uiteengezet: lees verder op ponzi.nl/biophytis-ontploft-integrage...
3.10 is ijsberg, kapot smelten!
Pharming als een rakte, grafiek Integragen super mooi en men gaat kopen nu de launch steeds dichterbij komt van hun product
Grow of partnerships in clinical genomics – Access new clinical genomic platforms as the sole or partner operator Enlarge digital genomics offering – Continue development of clinical sequencing offers such as circulating tumor exome, low DNA quantity – Develop & market bio informatics software – ICE launch in 2018 – Grow GeCo expertise and IT support Successfully Launch miRpredX test – Licensing partners in North America and Europe – CE marked kit launch in European countries Select R&D partnerships – Access to clinical trials relevant for miR-31 -3p biomarker in Colorectal and Lung cancer – Companion Dx agreement
ik zou ze alle drie lekker verkopen.
De handel in aandelen van Biophytis is opgeschort in afwachting van een nieuw persbericht Parijs (Frankrijk), Cambridge (Massachusetts, VS), 13 februari 2020, 08:00 CET - Biophytis SA (Euronext Growth Paris: ALBPS - FR0012816825) heeft Euronext Parijs gevraagd om de handel in haar aandelen vanaf vandaag 13 februari op te schorten 2020 vóór de opening van de beurs. ****
Zomaar een dag op slot.. Hoe kan dat nou? Afgelopen dagen immens gestegen dus hoop goed bericht. Zit er bewust niet groot in. Benieuwd of Biophytis morgen wel ´open´ is en wat het persbericht gaat zijn. Overname zou leuk zijn. Slecht nieuws dan maar pennystock voor een tijdje en wachten op een nieuwe uitbraak.
Schijnt morgen ook nog geen handel. Wordt dus maandag.
Press release Biophytis successfully completes a € 3.3 million capital increase to strengthen its financing structure Paris (France), Cambridge (USA), 14 February 2020 – 8am CET, Biophytis SA (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company with a primary focus on the development of its lead drug candidate, Sarconeos (BIO101) for the treatment of neuromuscular diseases, announced the completion of a private placement of new shares allowing it to achieve a capital increase of approximately €3.3 million. The transaction was conducted via a private placement, which was carried out on 12 February 2019 after the market closed. The common shares were purchased by institutional European and U.S. investors, most of them previously invested in Biophytis Terms of private placement This private placement resulted in the issuance of 12,394,071 new common shares via a capital increase, without preferential subscription rights, or 31.6% of the shares outstanding after the transaction. For illustration purposes, a shareholder holding 1% of the share capital of the Company prior to this capital increase will experience a decrease in its holding to approximately 0.684%, assuming no purchase by it of new common shares in this private placement. The price of the new common shares to be issued is €0.27 per share following an accelerated book building exercise. This price corresponds to a 29.5% discount to the weighted average Biophytis stock price over the last 10 trading sessions prior to private placement. Biophytis estimates the gross proceeds of the issuing to be €3,346,399.17 million. Following the capital increase, the shareholding structure will be as follows: Shareholders Before capital increase After capital increase Nb of shares % Nb of shares % Management Other than management Free float New shareholders TOTAL 1,560,937 5.82% 1,560,937 87,620 25,164,697 12,394,071 39,207,325 3.98% 0.22% 64.18% 31.61% 100.00% 87,620 25,164,697 - 0.33% 93.85% 0.00% 26,813,254 100.00% Use of funds Biophytis will use the net proceeds of the capital increase to strengthen its financial resources, in particular for the preparation of the MYODA clinical study in Duchenne Muscular Dystrophy (DMD), for which Sarconeos (BIO101) obtained an IND from the FDA in December 2019. This capital increase, along with the other financing instruments already in place, allows the company to secure its financial position beyond the next 12 months. Settlement-delivery and listing of new shares The settlement-delivery of the securities will take place on or about February 19, 2020, subject to the usual 1 Press release conditions. The new common shares should be admitted to trading on the regulated Euronext Paris market under the existing ISIN code of Biophytis common shares by no later than February 20, 2020. The new common shares, with a face value of €0.20 euro, will rank equally with the existing common shares of Biophytis. In accordance with Article 211-3 of the AMF General Regulation, this offer of financial securities did not require a prospectus subject to the AMF visa. Detailed regulatory information regarding the Company are available in the 2018 Annual report, accessible on its website: www.biophytis.com/ , including the entirety of chapter 4 regarding risks Stanislas Veillet, President and CEO of Biophytis, said: "We are pleased to announce that we have successfully received commitments for a capital increase of €3.3 million. This allows Biophytis to reinforce its financing structure, and in particular for the preparation of the MYODA clinical study in Duchenne Muscular Dystrophy (DMD), for which Sarconeos (BIO101) obtained an IND from the FDA in December. I want to thank our investors who have been following us for years and have not hesitated to invest again in Biophytis at a 73% premium to last week’s lowest share price” **** About BIOPHYTIS Biophytis SA is a clinically staged biotechnology company specializing in the development of drug candidates to slow down degenerative processes and improve functional abilities in patients with age-related diseases, particularly neuromuscular diseases. Sarconeos (BIO101), our leading drug candidate, is a small molecule, administered orally, currently in clinical phase 2b in sarcopenia (SARA-INT) in the United States and Europe. A pediatric formulation of Sarconeos (BIO101) is being developed for the treatment of Duchenne myopathy (DMD) for which the company received IND status by the U.S. Food and Drug Administration (FDA) in December 2019. The company is based in Paris, France, and Cambridge, Massachusetts. The company's common shares are listed on the Euronext Growth Paris market (Ticker: ALBPS -ISIN: FR0012816825). For more information www.biophytis.com. Warning This press release contains forward-looking statements. While the Company considers its projections to be based 2 This private placement was made pursuant to Article L. 411-2 II of the Monetary and Financial Code under the 12th resolution of the Extraordinary General Meeting of Shareholders held on August 8, 2019. The decision to conduct this capital increase was made by the Company's Board of Directors, at a meeting on 12 February 2020. This capital increase was made by issuing new common shares with the removal of the preferential right of subscription of shareholders in accordance with Article L. 225-136 of the Code of Commerce (by private placement of less than 20% of the company’s share capital). The private placement is led by H.C. Wainwright & Co. as the exclusive placement agent in the United States and Banque Delubac and Cie – CIB as an advisor and global coordinator of the transaction. Press release on reasonable assumptions, these forward-looking statements may be called into question by a number of hazards and uncertainties, so that actual results may differ materially from those anticipated in such forward- looking statements. For a description of the risks and uncertainties likely to affect the results, BIOPHYTIS' financial position, performance or achievements and thus cause a change from the forward-looking statements, please refer to the "Risk Factors" section of the Company's Equity Admission Prospectus for listing on the Euronext Growth market in Paris filed with the AMF and available on the AMF (www.amf-france.org) and BIOPHYTIS websites ( www.biophytis.com). This press release, and the information contained in it, does not constitute an offer to sell or subscribe, nor the solicitation of a purchase or subscription order, of BIOPHYTIS shares in any country. The elements contained in this communication may contain forward-looking information involving risks and uncertainties. The Company's actual achievements may differ materially from those anticipated in this information due to different risk and uncertainty factors. This press release was written in French and English; If there is a difference between the texts, the French version will prevail. Biophytis Contact for Investor Relations Evelyne Nguyen, CFO evelyne.nguyen@biophytis.com Tel:+33144272332 Media contact Citigate Dewe Rogerson Quentin DUSSART/Sylvie BERREBI/ Nathaniel DAHAN biophytis@citigatedewerogerson.com Tel:+33(0)155307091/+44(0)2076389571 3
ik blijf maar "rustig" zitten. In ieder geval weer leven in de brouwerij.:)
Vet balen. Op 55ct. ingestapt xD. Dat was zowat de top. Naja.. Genoeg moois in de pipeline en afgelopen maanden mooie PBs uitgekomen. Word niet voor niets voor vele $ in aandelen geïnvesteerd. Verkooporder 1EU ingesteld. Krijg vanzelf een mailtje wanneer die geactiveerd is :):)
DonSjon schreef op 15 februari 2020 13:29 :
Vet balen. Op 55ct. ingestapt xD. Dat was zowat de top. Naja.. Genoeg moois in de pipeline en afgelopen maanden mooie PBs uitgekomen. Word niet voor niets voor vele $ in aandelen geïnvesteerd.
Verkooporder 1EU ingesteld. Krijg vanzelf een mailtje wanneer die geactiveerd is :):)
Rustig op de plank laten liggen, kijk maar naar Pharming en Novacyt.
Press release Biophytis Launches COVA Clinical Study with Sarconeos (BIO101) in Covid-19 th Paris, (France), Cambridge (Massachusetts, United States), April 7 , 2020, 8:00 a.m. CEST - Biophytis SA (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company specialized in the development of drug candidates for treatment of aged related diseases, amongst which neuromuscular diseases, today announces that it is joining the global effort to fight the SARS-CoV-2 virus and its effects, by launching a new clinical development program: COVA, with Sarconeos (BIO101) as a potential treatment for respiratory failure associated with Covid-19. The COVA clinical program consists of evaluating the therapeutic efficacy and the safety of Sarconeos (BIO101) in the treatment of Acute Respiratory Distress Syndrome (ARDS) associated with COVID-19. The Phase 2/3 clinical trials are expected to start in the coming weeks in France, following approval from the French National Agency for the Safety of Medicines (ANSM- Agence Nationale de Sécurité du Médicament), and should then extend to Belgium and the United States. The first randomized patient is expected to be recruited at the Pitié-Salpêtrière Hospital, which is linked with Sorbonne University’s medical school, a long-standing partner of Biophytis. Sarconeos (BIO101) is a drug candidate that has demonstrated an excellent safety profile during the SARA development program which is evaluating its ability to improve muscle function in frail elderly patients with sarcopenia (the phase 2b study, SARA-INT, is currently underway). Sarconeos (BIO101) is also being developed to improve the respiratory function of children with Duchenne muscular dystrophy (DMD), Biophytis’ MYODA DMD program is expected to start in H2 2020. The COVA program builds on the clinical and preclinical data generated with Sarconeos (BIO101) in these neuromuscular diseases. Stanislas Veillet, President and CEO of Biophytis, said: “Covid-19 has completely transformed our society on a global scale, and has had a devastating effect particularly on the frail elderly. We are very eager to answer the calls from our industry and national and international organizations to join the global effort to fight this pandemic. Sarconeos (BIO101) has been shown to restore normal respiratory function in several experimental models by activating the renin-angiotensin system, the very one which is attacked by the SARS-Cov-2 virus. In the absence of a suitable vaccine or a proven antiviral therapy we believe that Sarconeos (BIO101) could offer an important potential treatment option for patients with acute respiratory failure associated with COVID-19, potentially limiting the need for ventilators and speeding up their potential recovery. We anticipate an approval from the ANSM (and potentially other regulatory bodies) to enable us to start our COVA program, allowing us to respond as quickly as possible to this health emergency.“ Press release The Coronavirus SARS-CoV-2 can cause ARDS by disrupting the renin angiotensin system (RAS), which has a key role in regulating respiratory function. It is believed that SARS-CoV-2 enters the lung cells using the Angiotensin 2 Converting Enzyme (ACE-2), a key enzyme in the RAS, inhibiting the system’s protective arm. Sarconeos (BIO101) activates the MAS receptor, a key component of the protective arm of the RAS, and has been shown to restore respiratory function in several preclinical models. **** About BIOPHYTIS Biophytis SA is a clinical-stage biotechnology company specialized in the development of drug candidates to slow down degenerative processes and improve functional abilities in patients with age-related diseases, especially neuromuscular diseases. Sarconeos (BIO101), our leading drug candidate, is a small molecule, administered orally, currently in clinical Phase 2b in sarcopenia (SARA-INT) in the United States and Europe. A pediatric formulation of BIO101 is being developed for the treatment of Duchenne Muscular Dystrophy (DMD). The company plans to start the clinical development in H2 2020. Sarconeos (BIO101) will also be developed as a treatment for Covid-19 (Coronavirus) for which the company has filed a clinical trial application with the French Regulatory Authority (ANSM). The company is based in Paris, France, and Cambridge, Massachusetts. The company's common shares are listed on the Euronext Growth Paris market (Ticker: ALBPS -ISIN: FR0012816825). For more information www.biophytis.com. Disclaimer This press release contains forward-looking statements. While the Company considers its projections to be based on reasonable assumptions, these forward-looking statements may be called into question by a number of hazards and uncertainties, so that actual results may differ materially from those anticipated in such forward-looking statements. For a description of the risks and uncertainties likely to affect the results, BIOPHYTIS' financial position, performance or achievements and thus cause a change from the forward-looking statements, please refer to the "Risk Factors" section of the Company's 2018 Annual Report available on BIOPHYTIS website ( www.biophytis.com). This press release, and the information contained in it, does not constitute an offer to sell or subscribe, nor the solicitation of a purchase or subscription order, of BIOPHYTIS shares in any country. The elements contained in this communication may contain forward-looking information involving risks and uncertainties. The Company's actual achievements may differ materially from those anticipated in this information due to different risk and uncertainty factors. This press release was written in French and English; If there is a difference between the texts, the French version will prevail. Biophytis Contact for Investor Relations Evelyne Nguyen, CFOevelyne.nguyen@biophytis.com Media contact Citigate Dewe Rogerson Sylvie Berrebi/ Nathaniel Dahan/ David Dible / Quentin Dussartbiophytis@citigatedewerogerson.com Tel: +44 (0) 20 7638 9571 / +33 (0)6 59 42 29 35 Press release
Zou het veel stijgen na dit weekend? Wat is jullie mening? Zou eventueel een klein koopje doen
Goudmijntje schreef op 9 april 2020 10:56 :
Zou het veel stijgen na dit weekend? Wat is jullie mening? Zou eventueel een klein koopje doen
Ik zou maar niet te lang wachten.
Ik ben nieuw op dit forum en heb drie weken geleden weer mijn eerste aandelen gekocht. Biophytis is er één van maar het verbaast mij een beetje dat hier nu zo weinig discussie over is. Novacyt ging vorige week als een raket en Biophytis zit een beetje in het zelfde segment maar bij Novacyt explodeerde de discussie. Naar mijn mening ging Biophytis ook als een raket en met het laatste nieuws dat Lekker Ding ook deelde heb ik wel vertrouwen dat deze de komende periode zal blijven stijgen. Zijn er hier mensen die een reden kunnen benoemen waarom je juist niet moet kopen?
Probeer eens wat meer informatie te verkrijgen op franse fora.
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
CVC Capital Partners
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Indices
AEX
882,27
-0,04%
EUR/USD
1,0723
+0,25%
FTSE 100
8.147,03
+0,09%
Germany40^
18.125,10
-0,20%
Gold spot
2.340,19
+0,10%
NY-Nasdaq Composite
15.927,90
+2,03%
Stijgers
Dalers